Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05006794 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
A Phase 1 study of Solid Malignancies, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 13
- Study locations
NCT05006794 is a Phase 1 study of Solid Malignancies that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 145 participants, above the 57-participant average among 3 other Solid Malignancies trials with a reported enrollment target (154% higher). The trial reports 13 study locations across 11 states.
The verdict
NCT05006794, a Phase 1 study of Solid Malignancies, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase I open-label, multi-center study of zamzetoclax (formerly GS-9716) tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of zamzetoclax, and characterize the safety and tolerability of zamzetoclax as monotherapy and in combination with anti-cancer therapies.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG zamzetoclax
- DRUG sacituzumab govitecan-hziy
Study Locations (13)
Other
- Rambam Health Care Campus - Haifa
- Hadassah Medical Center- Ein Kerem - Jerusalem
- Tel-Aviv Sourasky Medical Center - Tel Aviv
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) - Aurora
Florida
- Moffitt Cancer Center - Tampa
Michigan
- START Midwest - Grand Rapids
New York
- Montefiore Medial Center - Montefiore Medical Park - The Bronx
North Carolina
- Novant Health Cancer Institute - Elizabeth (Breast Cancer) - Charlotte
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Oregon
- Oregon Health Oregon Health & Sciences University-Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05006794
The ClinicalTrials.gov registry entry for NCT05006794 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 57-participant average among 3 other Solid Malignancies trials with a reported enrollment target (154% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT05006794 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Other, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT05006794 about?
NCT05006794 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies". This is a Phase I open-label, multi-center study of zamzetoclax (formerly GS-9716) tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose...
What is the current status of trial NCT05006794?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2021-09-15. Estimated completion is 2029-03.
What conditions does trial NCT05006794 study?
This clinical trial studies the following conditions: Solid Malignancies.
What interventions are being tested in trial NCT05006794?
The interventions under investigation include: Docetaxel (DRUG), zamzetoclax (DRUG), sacituzumab govitecan-hziy (DRUG).
Who is sponsoring clinical trial NCT05006794?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05006794 being conducted?
This trial has 13 study locations across Colorado, Florida, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.